Time filter

Source Type

New York City, NY, United States

Granato P.A.,SUNY Upstate Medical University | Granato P.A.,Laboratory Alliance of Central New York | Chen L.,Laboratory Alliance of Central New York | Holiday I.,Laboratory Alliance of Central New York | And 4 more authors.
Journal of Clinical Microbiology | Year: 2010

Campylobacter enteritis is a food-borne or waterborne illness caused almost exclusively by Campylobacter jejuni and, to a lesser extent, by Campylobacter coli. These organisms produce indistinguishable clinical diseases and together represent the second most common cause of bacterial diarrhea in the United States and the leading cause of enteric infection throughout the world. The conventional approach to the laboratory diagnosis of Campylobacter enteritis is based on the recovery of the organism from a stool specimen, which requires the use of a specialized medium incubated at 42°C for several days in an artificially created microaerophilic environment. Recently, several commercially available enzyme immunoassays (EIAs) have been developed for the direct detection of C. jejuni and C. coli in stool specimens. This study compared conventional culture with three EIA methods, the Premier CAMPY EIA (Meridian Bioscience, Cincinnati, OH), the ProSpecT Campylobacter EIA (Remel, Lenexa, KS), and the ImmunoCard STAT! CAMPY test (Meridian Bioscience, Cincinnati, OH), for the detection of C. jejuni and C. coli in 485 patient stool samples. Discordant results were arbitrated by using an in-house, real-time PCR assay that was developed and validated by a public health reference laboratory. Following analyses of the discrepant specimens by PCR, the sensitivity and specificity of both the Premier CAMPY and ProSpecT Campylobacter EIAs were 99.3% and 98%, respectively, while the ImmunoCard STAT! CAMPY test had a sensitivity of 98.5% and a specificity of 98.2%. By use of the PCR test as the reference standard, culture detected 127 of 135 Campylobacter-positive stool specimens, yielding a sensitivity of 94.1%. These results showed that the three EIAs evaluated in this study provide a rapid and reliable alternative for the laboratory diagnosis of enteric infections with C. jejuni and C. coli and that conventional culture may no longer be recognized as the "gold standard" for diagnosis. Copyright © 2010, American Society for Microbiology. All Rights Reserved.

Granato P.A.,SUNY Upstate Medical University | Granato P.A.,Laboratory Alliance of Central New York
Clinical Microbiology Newsletter | Year: 2010

Vaginitis is one of the most common diseases that affect women's health, with over 50% of women experiencing at least one episode of vaginal infection in their lifetime. Vaginal disease can be infectious, non-infectious, or chronic in nature. However, most cases of vaginitis are the result of infection that accounts for over 10 million physician office visits in the United States each year. Infectious vaginitis is most commonly grouped into three major categories of disease based upon microbial etiology: bacterial vaginosis, vaginal candidiasis, and vaginal trichomoniasis. Occasionally, the vulva is infected by these microorganisms, as well, and the disease is then called vulvovaginitis. Because these three infectious syndromes are caused by different groups of microorganisms, accurate and reliable diagnosis is necessary to institute appropriate treatment. The purpose of this article is to review the various types of vaginitis, discuss the pathogenesis and clinical presentation of each type of disease, and provide a brief summary of some of the various methods available for the laboratory diagnosis of infectious vaginitis. © 2010 Elsevier Inc.

Miller N.S.,Boston Medical Center | Miller N.S.,Boston University | Yen-Lieberman B.,Cleveland Clinic | Poulter M.D.,University of Virginia | And 3 more authors.
Journal of Clinical Virology | Year: 2012

Background: The novel IsoAmp® HSV Assay employs isothermal helicase-dependent nucleic acid amplification and a user-friendly disposable test device to achieve rapid (<1.5h), on-demand qualitative detection of herpes simplex virus (HSV) types 1 and 2 in oral and genital lesions. Objectives: To compare performance of the IsoAmp® HSV Assay with the ELVIS® HSV ID/typing (shell-vial culture and DFA) test system for clinical specimens collected from oral and genital lesions in symptomatic patients. Study design: A total of 994 specimens from male and female genital and oral lesions were obtained and evaluated at five study sites in the United States. Results from the IsoAmp® HSV Assay were compared to those from the ELVIS® system. Separate reproducibility studies were performed at 3 sites using a blinded and randomized study panel. Discrepant specimens were resolved by bidirectional sequencing analysis. Results: After discrepant analysis, overall agreement of IsoAmp® with ELVIS® was 98.8% with 37.0% overall prevalence (all study sites). Reproducibility rates were well within expectations. Conclusion: The IsoAmp® HSV Assay showed excellent performance for clinical use for detection of HSV in genital and oral specimens. In contrast to ELVIS®, IsoAmp® HSV offers excellent sensitivity plus rapid on-demand testing and simpler specimen preparation. © 2012 Elsevier B.V.

Granato P.A.,Laboratory Alliance of Central New York | Granato P.A.,SUNY Upstate Medical University | Alkins B.R.,Laboratory Alliance of Central New York | Yen-Lieberman B.,Cleveland Clinic | And 4 more authors.
Journal of Clinical Microbiology | Year: 2015

The AmpliVue HSV 1+2 assay was compared to the ELVIS HSV ID and D3 Typing Culture System for the qualitative detection and differentiation of herpes simplex virus 1 (HSV-1) and HSV-2 DNA in 1,351 cutaneous and mucocutaneous specimens. Compared to ELVIS, AmpliVue had sensitivities of 95.7 and 97.6% for detecting HSV-1 and HSV-2, respectively. Following arbitration of discordant results by an independent molecular method, the AmpliVue assay had a resolved sensitivity and specificity of 99.2 and 99.7%, respectively, for both HSV-1 and HSV-2, whereas ELVIS had a resolved sensitivity of 87.1% for HSV-1 and 84.5% for HSV-2. © 2015, American Society for Microbiology.

Beck E.T.,Dynacare Laboratories | Buchan B.W.,Dynacare Laboratories | Buchan B.W.,Medical College of Wisconsin | Riebe K.M.,Dynacare Laboratories | And 4 more authors.
Journal of Clinical Microbiology | Year: 2014

Clostridium difficile is a Gram-positive bacterium commonly found in health care and long-term-care facilities and is the most common cause of antibiotic-associated diarrhea. Rapid detection of this bacterium can assist physicians in implementing contact precautions and appropriate antibiotic therapy in a timely manner. The purpose of this study was to compare the clinical performance of the Quidel Lyra Direct C. difficile assay (Lyra assay) (Quidel, San Diego, CA) to that of a direct cell culture cytotoxicity neutralization assay (CCNA) and enhanced toxigenic culture. This study was performed at three geographically diverse laboratories within the United States using residual stool specimens submitted for routine C. difficile testing. Residual samples were tested using the Lyra assay on three real-time PCR platforms, and results were compared to those for direct CCNA and enhanced toxigenic culture. The test results for all platforms were consistent across all three test sites. The sensitivity and specificity of the Lyra assay on the SmartCycler II, ABI 7500 Fast DX, and ABI QuantStudio DX instruments compared to CCNA were 90.0% and 93.3%, 95.0% and 94.2%, and 93.8% and 95.0%, respectively. Compared to enhanced toxigenic culture, the sensitivity and specificity of the Lyra assay on the SmartCycler II, ABI 7500, and QuantStudio instruments were 82.1% and 96.9%, 89.3% and 98.8%, and 85.7% and 99.0%, respectively. Overall, the Lyra assay is easy to use and versatile and compares well to C. difficile culture methods. © 2014 American Society for Microbiology. All Rights Reserved.

Discover hidden collaborations